跳至主要内容
临床试验/NCT00232154
NCT00232154已完成2 期

An Open-Label Study Of Azithromycin Pharmacokinetics In Sinus Mucosal Tissue And Plasma In Subjects With Chronic Rhinosinusitis Following A Single 2g Dose Of Azithromycin Extended Release For Oral Suspension Or Azithromycin 500mg Tablet Formulation Once Daily For A Maximum Of Three Days

Pfizer19 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2005年11月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Pfizer
入组人数
72
试验地点
19
主要终点
To characterize the pharmacokinetics of azithromycin in sinus mucosal tissue and plasma in adult subjects after treatment with a single 2 g oral dose of azithromycin extended release for oral suspension or oral azithromycin 500 mg tablet

研究概览

简要总结

To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects considered by the Principal Investigator as an appropriate candidate for endoscopic sinus surgery, e.g., for the removal of the thickened and diseased mucosal tissue that blocks the ostiomeatal complex (OMC).

排除标准

  • Known or suspected hypersensitivity or intolerance to any macrolide-like compound, including erythromycin, clarithromycin, azithromycin or telithromycin.

结局指标

主要结局

To characterize the pharmacokinetics of azithromycin in sinus mucosal tissue and plasma in adult subjects after treatment with a single 2 g oral dose of azithromycin extended release for oral suspension or oral azithromycin 500 mg tablet

次要结局

  • To assess the safety of azithromycin extended release for oral suspension and azithromycin 500mg tablets.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (19)

Loading locations...

相似试验

A Study To Measure The Level Of Drug In Nasal Tissue... | 临床试验